Navigation Links
Bone Drugs May Beat Back Breast Cancer

Bisphosphonates seem to prevent recurrence, researchers find

THURSDAY, Dec. 10 (HealthDay News) -- Bone-building drugs used by tens of millions of women to fight osteoporosis also cut the risk of breast cancer, suggesting the drugs may play a dual role in keeping women healthy.

"Bone loss and potential fractures are a known complication of breast cancer therapy. Our feeling is that bisphosphonates may actually prevent disease recurrence through a variety of mechanisms," said Dr. Adam Brufsky, associate director of clinical investigation at the University of Pittsburgh Cancer Institute.

Brufsky authored one of several studies exploring the role of bone-building drugs in breast cancer prevention that were to be presented Thursday at the San Antonio Breast Cancer Symposium.

Bisphosphonates are already used to treat complications that result from breast cancer spreading to the bones.

One study looked at more than 150,000 postmenopausal women who participated in the U.S. government-led Women's Health Initiative (WHI).

The women taking bisphosphonates, namely Fosamax (alendronate), had a 32 percent reduction in their rate of invasive breast cancer compared to women who were not taking one of these drugs.

The University of California, Los Angeles, researchers were able to control for the fact that women with low bone mineral density are already at lower risk for breast cancer.

Because the study was not a randomized, controlled one, said lead investigator Dr. Rowan Chlebowski, a professor and medical oncologist with UCLA, "the findings are not definitive but they do provide a strong signal."

In another study, Israeli researchers found that postmenopausal women taking bisphosphonates for one or more years had a 29 percent reduction in their risk of breast cancer.

And the tumors that did appear tended to be estrogen receptor-positive and thus easier to treat than estrogen receptor-negative tumors.

And in other news from the symposium:

  • Researchers from the University of Pittsburgh Cancer Institute, led by Brufsky, concluded that zoledronic acid, another bisphosphonate, is safe and effective for use by postmenopausal women with breast cancer who are being treated with aromatase inhibitors. Bone mineral density increased 6.2 percent in women taking zoledronic acid, compared with 2.4 percent in the control group. Fractures were also reduced slightly in the treatment group, but it's unclear how significant this was. Zoledronic acid is marketed under several brand names, including Zometa.
  • A new drug, denosumab, a monoclonal antibody, performed better than zoledronic acid in easing problems associated with the spread of breast cancer to the bones.
  • A final study found that it was safe to give zoledronic acid to women with breast cancer being treated with the aromatase inhibitor Femara (letrozole) before surgery. No clear indication emerged as to whether the dual treatment was effective, however.

More information

The National Cancer Institute has more on breast cancer.

SOURCES: Dec. 9, 2009, teleconference with: Rowan Chlebowski, M.D., Ph.D., medical oncologist, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center, and Adam Brufsky, M.D., Ph.D., associate professor, medicine, associate chief, hematology-oncology, and associate director, clinical investigation, University of Pittsburgh Cancer Institute

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. AIDS Drugs Dont Need Routine Lab Monitoring
2. Statement of HDMA President and CEO John M. Gray on the Importation of Prescription Drugs
3. Case Western Reserve to receive $19.7m to study tuberculosis treatment drugs
4. Makes Ordering Drugs Online Safe and Affordable
5. Second-line CML drugs evoke faster response than front-line therapy
6. Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy
7. Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD
8. Diabetes Drugs Go Head-to-Head in Study
9. Continues Global Sales Expansion to More Than 3.5 Billion International Consumers
10. China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009
11. Coverage of inexpensive drugs may increase length and quality of life after heart attack
Post Your Comments:
(Date:10/13/2015)... ... , ... The Bill Howe Family of Companies is an award winning HVAC ... remediation services. Family-owned and operated for 35 years, they have maintained value, ethics and ... two years in a row from the Union Tribune Reader’s Poll, a Healthiest Company ...
(Date:10/13/2015)... ... 13, 2015 , ... Doulagivers is O'Brien's licensed training program ... End of Life Doula Training. A Doulagiver is a non-medical person trained to ... Based on her #1 International bestselling book Creating Positive Passings & The Level ...
(Date:10/12/2015)... (PRWEB) , ... October 13, 2015 , ... North American ... (IBC) at the 2015 IBC National Meeting in Rosemont, IL on October 4th. ... dedication, quality, and standards of excellence that customers have come to expect from members ...
(Date:10/12/2015)... ... October 12, 2015 , ... According to an ... female athletes, particularly in the area of track and field, are at a ... than male peers in the same age group. Dr. Steven Meier of Meier ...
(Date:10/12/2015)... ... 12, 2015 , ... The American Society of Clinical Hypnosis ... education and clinical training in a health care discipline. , Many practitioners ... as: losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements and ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... Corporation (NASDAQ: LMNX ) today announced that it expects ... 2015 on Monday, November 2, 2015. A press release announcing ... trading. --> --> ... highlights and financial results for the third quarter ended September ... time. . Simply log on to ...
(Date:10/12/2015)...  Millions of smokers worldwide have used vaping to ... An April 2015 study released by a ... cigarettes to be up to 95 percent less harmful ... after the technology was first introduced the potentially harmful ... --> --> Palm Beach Vapors, ...
(Date:10/12/2015)...  In a Sutter Institute of Medical Research study ... and Psychiatry, the blood product intravenous immunoglobulin, or IVIG, ... in patients in the early, pre-dementia phase of Alzheimer,s ... IVIG, extracted from the plasma of more than 1,000 ... protein found in patients with Alzheimer,s disease. Sutter Institute ...
Breaking Medicine Technology: